Isoantibodies

• 

  Subject Areas on Research

  • 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. 
  • A 2020 Banff Antibody-mediatedInjury Working Group examination of international practices for diagnosing antibody-mediated rejection in kidney transplantation - a cohort study. 
  • A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation. 
  • Absence of donor MHC antigen expression ameliorates chronic kidney allograft rejection. 
  • Allo-Specific Humoral Responses: New Methods for Screening Donor-Specific Antibody and Characterization of HLA-Specific Memory B Cells. 
  • Alloimmunization in sickle cell disease: changing antibody specificities and association with chronic pain and decreased survival. 
  • Allosensitization in cardiac transplantation: shooting at a moving target. 
  • Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. 
  • Amplification of suppressor inducer pathway with monoclonal antibody, anti-2H4, identifying a novel epitope of the common leukocyte antigen/T200 antigen. 
  • Anti-Angiotensin II Type 1 Receptor and Anti-Endothelial Cell Antibodies: A Cross-Sectional Analysis of Pathological Findings in Allograft Biopsies. 
  • Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromes. 
  • Antibody depletion strategy for the treatment of suspected antibody-mediated rejection in lung transplant recipients: Does it work? 
  • Antibody desensitization therapy in highly sensitized lung transplant candidates. 
  • Antibody-Mediated Rejection in Sensitized Nonhuman Primates: Modeling Human Biology. 
  • Antibody-coated erythrocytes induce secretion of tumor necrosis factor by human monocytes: a mechanism for the production of fever by incompatible transfusions. 
  • Antibody-mediated rejection of the lung: A consensus report of the International Society for Heart and Lung Transplantation. 
  • Antibody-mediated rejection--an ounce of prevention is worth a pound of cure. 
  • B cells in transplant tolerance and rejection: friends or foes? 
  • BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation. 
  • Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. 
  • Banff Lung Report: Current knowledge and future research perspectives for diagnosis and treatment of pulmonary antibody-mediated rejection (AMR). 
  • Banff study of pathologic changes in lung allograft biopsy specimens with donor-specific antibodies. 
  • Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function. 
  • Biochemical characterization of antibodies submitted as reactive with glycophorin species. 
  • CD68/CD31 immunohistochemistry double stain demonstrates increased accuracy in diagnosing pathologic antibody-mediated rejection in cardiac transplant patients. 
  • CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. 
  • CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8. 
  • Captopril-enhanced binding of PlA1 (HPA-1a) antibodies in posttransfusion purpura. 
  • Casting a smaller net into a bigger donor pool: A single center's experience with the new kidney allocation system. 
  • Cellular immunology markers postransplantation predictive of long-term graft outcome. 
  • Center-level Variation in HLA-incompatible Living Donor Kidney Transplantation Outcomes. 
  • Characterization of a monoclonal antibody that defines an immunoregulatory T cell subset for immunoglobulin synthesis in humans. 
  • Class II alloantibody and mortality in simultaneous liver-kidney transplantation. 
  • Clinical relevance and IgG subclass determination of non-HLA antibodies identified using endothelial cell precursors isolated from donor blood. 
  • Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation. 
  • Comparison of PRA-STAT, sHLA-EIA, and anti-human globulin-panel reactive antibody to identify alloreactivity in pretransplantation sera of heart transplant recipients: correlation to rejection and posttransplantation coronary artery disease. 
  • Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia. 
  • Cross-reactivity of primate alloantigens: absorption of anti-HL-A reactivity from human alloantisera by chimpanzee lymphocytes. 
  • Current challenges and opportunities in the management of antibody-mediated rejection in lung transplantation. 
  • Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use. 
  • Desensitization and management of allograft rejection. 
  • Detection of platelet isoantibodies by (3H)serotonin platelet release and its clinical application to the problem of platelet matching. 
  • Determination of human platelet antigen typing by molecular methods: Importance in diagnosis and early treatment of neonatal alloimmune thrombocytopenia. 
  • Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. 
  • Development of donor-specific and non-donor-specific HLA-DP antibodies post-transplant: the role of epitope sharing and epitope matching. 
  • Differential effects of donor-specific alloantibody. 
  • Does a febrile reaction to platelets predispose recipients to red blood cell alloimmunization? 
  • Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. 
  • Donor-specific HLA-antibody-mediated humoral rejection in a liver transplant recipient fully reversed with plasmapheresis and immunoglobulin. 
  • Early acute antibody-mediated rejection of a negative flow crossmatch 3rd kidney transplant with exclusive disparity at HLA-DP. 
  • Effect of sensitization in US heart transplant recipients bridged with a ventricular assist device: update in a modern cohort. 
  • Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization. 
  • Enhanced de novo alloantibody and antibody-mediated injury in rhesus macaques. 
  • Eplet mismatch scores and de novo donor-specific antibody development in simultaneous pancreas-kidney transplantation. 
  • Experimental transfusion reactions in monkeys: haemolytic, coagulant and renal effects of transfused isoimmune IgG and IgM. 
  • Gene therapy with an E2F transcription factor decoy inhibits cell cycle progression in rat anti-Thy 1 glomerulonephritis. 
  • HLA antibodies and soluble CD30 are associated with poor renal graft outcome: updated results of a single-center cross-sectional study. 
  • Hemolytic transfusion reactions caused by failure of commercial antiglobulin reagents to detect complement. 
  • Hepatic transplantation into sensitized recipients. Demonstration of hyperacute rejection. 
  • High-dose intravenous immunoglobulin for severe platelet alloimmunization. 
  • Histocompatibility testing and mixed lymphocyte culture responses in chimpanzee families. 
  • Histopathologic changes in anti-angiotensin II type 1 receptor antibody-positive kidney transplant recipients with acute rejection and no donor specific HLA antibodies. 
  • Hospital readmissions following HLA-incompatible live donor kidney transplantation: A multi-center study. 
  • Human B cell alloantigens: expression of MB and MT determinants. 
  • Human lymphocyte antigens: production of a monoclonal antibody that defines functional thymus-derived lymphocyte subsets. 
  • IDEC-131 (anti-CD154), sirolimus and donor-specific transfusion facilitate operational tolerance in non-human primates. 
  • IVIG therapy in neonatal isoimmune thrombocytopenic purpura and alloimmunization thrombocytopenia. 
  • Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF. 
  • IgG4 donor-specific HLA antibody profile is associated with subclinical rejection in stable pediatric liver recipients. 
  • Immune hemolytic transfusion reactions in monkeys: activation of the kallikrein system. 
  • Improved renal function in mouse kidney allografts lacking MHC class I antigens. 
  • In vivo tumor localization using tumor-specific monkey xenoantibody, alloantibody, and murine monoclonal xenoantibody. 
  • Induction of tolerance to solubilized rat histocompatibility antigens. 
  • Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. 
  • Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations. 
  • Intravenous immunoglobulin and plasmapheresis in acute humoral rejection: experience in renal allograft transplantation. 
  • Isoantibody specificity in post-transfusion purpura. 
  • Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: Evidence from cell-free DNA analysis. 
  • Lung Transplantation and the Era of the Sensitized Patient. 
  • Lutheran antigens, CD44-related antigens, and Lutheran regulatory genes. 
  • Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies. 
  • Measuring the Impact of Targeting FcRn-Mediated IgG Recycling on Donor-Specific Alloantibodies in a Sensitized NHP Model. 
  • Mediation of hyperacute rejection of rat hepatic allografts by RT-1 antigens. 
  • Meeting report of the STAR-Sensitization in Transplantation Assessment of Risk: Naïve Abdominal Transplant Organ subgroup focus on kidney transplantation. 
  • Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. 
  • Neonatal alloimmune thrombocytopenic purpura. 
  • Neonatal alloimmune thrombocytopenic purpura: a case report. 
  • Non-HLA antibodies in transplantation: when do they matter? 
  • Nontoxic nerve guide tubes support neovascular growth in transected rat optic nerve. 
  • Overcoming Chronic Rejection-Can it B? 
  • PAS-C platelets contain less plasma protein, lower anti-A and anti-B titers, and decreased HLA antibody specificities compared to plasma platelets. 
  • Patterns of de novo allo B cells and antibody formation in chronic cardiac allograft rejection after alemtuzumab treatment. 
  • Perception of low-titer group A plasma and potential barriers to using this product: A blood center's experience serving community and academic hospitals. 
  • Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation. 
  • Phase 2, randomized, double-blind, placebo-controlled, multicenter clinical evaluation of recombinant human thrombin in multiple surgical indications. 
  • Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study. 
  • Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. 
  • Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients. 
  • Prevention of graft-versus-host disease by a novel immunosuppressant, PG490-88, through inhibition of alloreactive T cell expansion. 
  • Prevention trumps treatment of antibody-mediated transplant rejection. 
  • Prolonged survival of class II transactivator-deficient cardiac allografts. 
  • Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. 
  • Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group. 
  • Red blood cell alloimmunization mitigation strategies. 
  • Reduced antigenicity of formaldehyde-fixed arterial allografts and their potential clinical application. 
  • Region-specific anti-thyroid hormone receptor (TR) antibodies detect changes in TR structure due to ligand-binding and dimerization. 
  • Residual risk of D alloimmunization: is it time to feel safe about platelets from D+ donors? 
  • Role of C1q complement fixing antibody assay in therapeutic plasma exchange management of pediatric cardiac antibody mediated rejection. 
  • Seasonal variability is not observed in the rates of high anti-A and anti-B titers in plasma, apheresis platelet, and whole blood units tested by different methods. 
  • Seek and you will find: antibody and the liver. 
  • Sensitization and Desensitization in Vascularized Composite Allotransplantation. 
  • Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. 
  • Sensitization in transplantation: Assessment of risk (STAR) 2019 Working Group Meeting Report. 
  • Serological and biochemical characterization of monoclonal antibodies against red cell markers related to expression of Lutheran blood group antigens. 
  • Serum immunoglobulins. 3. Abnormalities associated with chronic urticaria in children. 
  • Significance of complement split product C4d in ABO-compatible liver allograft: diagnosing utility in acute antibody mediated rejection. 
  • Splenic Irradiation for the Treatment of Severe Antibody-Mediated Rejection. 
  • Spotlight on pathogenesis of TRALI: HNA-3a (CTL2) antibodies. 
  • Studies investigating pretransplant donor-specific blood transfusion, rapamycin, and the CD154-specific antibody IDEC-131 in a nonhuman primate model of skin allotransplantation. 
  • Successful treatment of immune thrombocytopenic purpura with anti-D antibody following a cadaveric liver transplant for hepatoblastoma. 
  • The Virtual Crossmatch: An Essential Tool for Transplanting Sensitized Patients. 
  • The association of enhancement of renal allograft survival by donor-specific blood transfusion with host MHC-linked inhibition of IgG anti-donor class I alloantibody responses. 
  • The clinical relevance of alloantibody in liver transplantation. 
  • The effect of soluble complement receptor type 1 on hyperacute allograft rejection. 
  • The problem of transplanting the sensitized patient: whose problem is it? 
  • The role of B cells in solid organ transplantation. 
  • The role of class I major histocompatibility complex antigens in prolonging the survival of hepatic allografts in the rat. 
  • The role of donor-specific HLA alloantibodies in liver transplantation. 
  • Therapeutic apheresis in kidney transplantation: a review of renal transplant immunobiology and current interventions with apheresis medicine. 
  • Thromboxane augmentation of alloreactive T cell function. 
  • Transplanting the highly sensitized patient: trials and tribulations. 
  • Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates. 
  • Two classes of germline genes both derived from the V(H)1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII. 
  • Using donor exchange paradigms with desensitization to enhance transplant rates among highly sensitized patients. 
  • Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens. 
  • Vincristine therapy for severe platelet alloimmunization. 
  • [Association between HSV-2 infection and serum anti-rat brain antibodies in patients with autism].